| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Ophthalmology, Nagoya City University Medical School, Nagoya, Japan.
PURPOSE. To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP).
METHODS. The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP from the implant was evaluated by high-performance liquid chromatography (HPLC). The implants were placed into a scleral pocket in the rabbit’s eye. The concentrations of BP in the aqueous humor, vitreous, and retina-choroid were measured by HPLC. The toxicity and biocompatibility of the implant were evaluated by slit lamp examination, electroretinography, and light microscopy.
RESULTS. In vitro studies demonstrated that the implants released BP in a biphasic pattern for at least 8 weeks. The BP concentrations in the vitreous and the retina-choroid remained within the concentration range capable of suppressing inflammatory responses for more than 8 weeks. The BP concentration was greater in the retina-choroid than in the vitreous. In the aqueous humor, BP was below the detection limit during the observation period. No significant toxicity to the retina was observed. Also, the implant showed good biocompatibility in the eye.
CONCLUSIONS. These results suggest that the intrascleral implant would be a promising system for delivery of steroid to the posterior segment of the eye.
This article has been cited by other articles:
|
|
 |
|
  A. Silva-Cunha, S. L. Fialho, M.-C. Naud, and F. Behar-Cohen Poly-{epsilon}-Caprolactone Intravitreous Devices: An In Vivo Study Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2312 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Short Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations Toxicol Pathol, January 1, 2008; 36(1): 49 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Kim, C. J. Galban, R. J. Lutz, R. L. Dedrick, K. G. Csaky, M. J. Lizak, N. S. Wang, G. Tansey, and M. R. Robinson Assessment of Subconjunctival and Intrascleral Drug Delivery to the Posterior Segment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 808 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Gilger, J. H. Salmon, D. A. Wilkie, L. P. J. Cruysberg, J. Kim, M. Hayat, H. Kim, S. Kim, P. Yuan, S. S. Lee, et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2596 - 2605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okabe, H. Kimura, J. Okabe, A. Kato, H. Shimizu, T. Ueda, S. Shimada, and Y. Ogura Effect of Benzalkonium Chloride on Transscleral Drug Delivery Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 703 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kato, H. Kimura, K. Okabe, J. Okabe, N. Kunou, and Y. Ogura Feasibility of Drug Delivery to the Posterior Pole of the Rabbit Eye with an Episcleral Implant Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okabe, H. Kimura, J. Okabe, A. Kato, N. Kunou, and Y. Ogura Intraocular Tissue Distribution of Betamethasone after Intrascleral Administration Using a Non-biodegradable Sustained Drug Delivery Device Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2702 - 2707. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
